CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients
Introduction: CIGB-258 is an immunomodulatory peptide with anti-inflammatory properties. Objectives: To establish the therapeutic schedule with CIGB-258 peptide for COVID-19 critically ill patients. In addition, to define the criteria for use and schedule of this peptide for COVID-19 seriously ill p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Editorial Ciencias Médicas - ECIMED
2020-10-01
|
| Series: | Revista Cubana de Medicina Militar |
| Subjects: | |
| Online Access: | http://www.revmedmilitar.sld.cu/index.php/mil/article/view/926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850262919766343680 |
|---|---|
| author | Rafael Venegas Rodríguez Rubén Peña Ruiz Raúl Santana Sánchez Mónica Bequet-Romero Mabel Hernández-Cedeño Beatriz Santiesteban Licea Ariana García Pedro Rafel Aroche de Dios Daniela Oliva Pérez Leticia Rosario Cruz Idelsis Esquivel Moynelo Maura García Sánchez Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta |
| author_facet | Rafael Venegas Rodríguez Rubén Peña Ruiz Raúl Santana Sánchez Mónica Bequet-Romero Mabel Hernández-Cedeño Beatriz Santiesteban Licea Ariana García Pedro Rafel Aroche de Dios Daniela Oliva Pérez Leticia Rosario Cruz Idelsis Esquivel Moynelo Maura García Sánchez Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta |
| author_sort | Rafael Venegas Rodríguez |
| collection | DOAJ |
| description | Introduction: CIGB-258 is an immunomodulatory peptide with anti-inflammatory properties.
Objectives: To establish the therapeutic schedule with CIGB-258 peptide for COVID-19 critically ill patients. In addition, to define the criteria for use and schedule of this peptide for COVID-19 seriously ill patients.
Methods: 9 critically ill patients and 3 seriously ill patients were included in this study. Clinical, radiological and laboratory evaluations were recorded according to the established protocol. Serum samples were obtained before and after treatment with CIGB-258, for the determination of the inflammation biomarkers.
Results: The therapeutic protocol was established with the CIGB-258 peptide, which consists of intravenous administration of 1 mg of peptide every 12 hours for critically ill patients. The dose should be increased to 2 mg every 12 hours, for patients who do not show clinical and radiological improvement in 24 hours. After extubation, patients should receive 1 mg of CIGB-258 daily, for another three days. Seriously ill patients should receive 1 mg of CIGB-258 every 12 hours, until their clinical condition resolves.
Conclusions: CIGB-258 showed an excellent safety profile. The established therapeutic protocol contributed to all critically ill patients recovering from respiratory distress and being extubated. Seriously ill patients improved considerably. The levels of the biomarkers associated with hyperinflammation and cytokines decreased significantly during treatment. |
| format | Article |
| id | doaj-art-bbc2ffd1daa040298becb1ca3dbb36f7 |
| institution | OA Journals |
| issn | 1561-3046 1561-3046 |
| language | Spanish |
| publishDate | 2020-10-01 |
| publisher | Editorial Ciencias Médicas - ECIMED |
| record_format | Article |
| series | Revista Cubana de Medicina Militar |
| spelling | doaj-art-bbc2ffd1daa040298becb1ca3dbb36f72025-08-20T01:55:05ZspaEditorial Ciencias Médicas - ECIMEDRevista Cubana de Medicina Militar1561-30461561-30462020-10-01494e0200926e0200926324CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patientsRafael Venegas Rodríguez0Rubén Peña Ruiz1Raúl Santana Sánchez2Mónica Bequet-Romero3Mabel Hernández-Cedeño4Beatriz Santiesteban Licea5Ariana García6Pedro Rafel Aroche de Dios7Daniela Oliva Pérez8Leticia Rosario Cruz9Idelsis Esquivel Moynelo10Maura García Sánchez11Gillian Martínez-Donato12Gerardo Guillén-Nieto13María del Carmen Domínguez Horta14Hospítal Militar Central Dr. Luis Díaz SotoHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaHospital Militar Central "Dr. Luis Díaz Soto". Habana del Este, La HabanaCIGBCIGBCIGBCIGBCIGBIntroduction: CIGB-258 is an immunomodulatory peptide with anti-inflammatory properties. Objectives: To establish the therapeutic schedule with CIGB-258 peptide for COVID-19 critically ill patients. In addition, to define the criteria for use and schedule of this peptide for COVID-19 seriously ill patients. Methods: 9 critically ill patients and 3 seriously ill patients were included in this study. Clinical, radiological and laboratory evaluations were recorded according to the established protocol. Serum samples were obtained before and after treatment with CIGB-258, for the determination of the inflammation biomarkers. Results: The therapeutic protocol was established with the CIGB-258 peptide, which consists of intravenous administration of 1 mg of peptide every 12 hours for critically ill patients. The dose should be increased to 2 mg every 12 hours, for patients who do not show clinical and radiological improvement in 24 hours. After extubation, patients should receive 1 mg of CIGB-258 daily, for another three days. Seriously ill patients should receive 1 mg of CIGB-258 every 12 hours, until their clinical condition resolves. Conclusions: CIGB-258 showed an excellent safety profile. The established therapeutic protocol contributed to all critically ill patients recovering from respiratory distress and being extubated. Seriously ill patients improved considerably. The levels of the biomarkers associated with hyperinflammation and cytokines decreased significantly during treatment.http://www.revmedmilitar.sld.cu/index.php/mil/article/view/926covi-19tormenta de citocinashiperinflamaciónhsp60cigb-258jusvinza. |
| spellingShingle | Rafael Venegas Rodríguez Rubén Peña Ruiz Raúl Santana Sánchez Mónica Bequet-Romero Mabel Hernández-Cedeño Beatriz Santiesteban Licea Ariana García Pedro Rafel Aroche de Dios Daniela Oliva Pérez Leticia Rosario Cruz Idelsis Esquivel Moynelo Maura García Sánchez Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients Revista Cubana de Medicina Militar covi-19 tormenta de citocinas hiperinflamación hsp60 cigb-258 jusvinza. |
| title | CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients |
| title_full | CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients |
| title_fullStr | CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients |
| title_full_unstemmed | CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients |
| title_short | CIGB-258 immunomodulatory peptide for the treatment of critical and severe COVID-19 patients |
| title_sort | cigb 258 immunomodulatory peptide for the treatment of critical and severe covid 19 patients |
| topic | covi-19 tormenta de citocinas hiperinflamación hsp60 cigb-258 jusvinza. |
| url | http://www.revmedmilitar.sld.cu/index.php/mil/article/view/926 |
| work_keys_str_mv | AT rafaelvenegasrodriguez cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT rubenpenaruiz cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT raulsantanasanchez cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT monicabequetromero cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT mabelhernandezcedeno cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT beatrizsantiestebanlicea cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT arianagarcia cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT pedrorafelarochededios cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT danielaolivaperez cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT leticiarosariocruz cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT idelsisesquivelmoynelo cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT mauragarciasanchez cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT gillianmartinezdonato cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT gerardoguillennieto cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients AT mariadelcarmendominguezhorta cigb258immunomodulatorypeptideforthetreatmentofcriticalandseverecovid19patients |